STOCK TITAN

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Harbour BioMed (HKEX: 02142) announced that partner Spruce Biosciences (Nasdaq: SPRB) separated its CRHX-101 antibody program into Adrenyx Biosciences, a wholly-owned subsidiary.

Adrenyx is expected to list on Nasdaq in the first half of 2027. Harbour BioMed expects equity interests in both companies after the planned pro rata distribution of Adrenyx shares to Spruce shareholders. Adrenyx secured an initial US$5 million through secured convertible notes; planned equity financing includes up to US$50 million from the notes investor, inclusive of notes funding. CRHX-101 is being developed for classic congenital adrenal hyperplasia. Next steps include nonclinical and manufacturing work, an FDA Investigational New Drug application and then clinical development.

Loading...
Loading translation...
4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.HBMAT's license agreement provides eligibility for up to US$395 million in payments, plus tiered future sales royalties. 3.4× market cap
  • Moderate pointCRHX-101's separation into Adrenyx establishes a dedicated company for the Harbour-originated antibody program.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Harbour BioMed expects interests in both Spruce and Adrenyx after the planned share distribution.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Adrenyx plans nonclinical and manufacturing work, an FDA investigational application and subsequent clinical development for CRHX-101.

Negative

  • Minor pointHarbour BioMed's expected Adrenyx equity interest depends on completion of the planned pro rata distribution.

News Explained

Harbour BioMed’s separation announcement also discloses contract economics: HBMAT licensed CRHX-101 to Spruce in January 2025, with eligibility for up to US$395 million in upfront and milestone payments plus tiered royalties, along with a warrant granted to HBMAT for a minority interest in Spruce that Harbour says its subsidiary exercised in January 2026.

Key Figures

Initial secured convertible notes: US$5 million Aggregate note principal: Up to US$10 million Private placement funding: Up to US$50 million +2 more
Initial secured convertible notes
US$5 million
Initial funding under the note purchase arrangement
Aggregate note principal
Up to US$10 million
Potential total under the secured convertible note arrangement
Private placement funding
Up to US$50 million
Expected in connection with the planned distribution; inclusive of notes funding
Milestone payments
Up to US$395 million
Eligible under the January 2025 collaboration and license agreement
Expected Nasdaq listing
First half of 2027
Adrenyx

Historical Context

1 past event · Latest: Nov 09
1 event
  1. Nov 09

    Program separation

    24h Move
    +6.0%

    Spruce transferred CRHX-101 to Adrenyx and outlined a first-half 2027 pro rata distribution.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

monoclonal antibody, glucocorticoid, investigational new drug application, convertible note, +1 more
5 terms
monoclonal antibody medical
"CRHX-101 is a monoclonal antibody designed to selectively neutralize corticotropin-releasing hormone"
A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.
glucocorticoid medical
"reduce patients' reliance on chronic high-dose glucocorticoid therapy"
A glucocorticoid is a type of steroid hormone—produced naturally by the body and also made as a medicine—that quiets inflammation and helps control how the body uses energy and responds to stress. Investors watch glucocorticoids because they are widely used drugs whose effectiveness, side effects and regulatory approval or supply issues can drive sales, affect healthcare costs and change demand for related treatments, much like a widely used tool that can both fix a problem and create new ones.
investigational new drug application regulatory
"the filing of an Investigational New Drug application for CRHX-101"
An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.
convertible note financial
"under a secured convertible note purchase arrangement"
A convertible note is a type of loan that a company gets from investors, which can later be turned into company shares instead of being paid back in cash. It matters because it helps startups raise money quickly without setting a fixed value for the company right away, making it easier to grow and attract investors.
chemistry, manufacturing and controls technical
"completion of IND-enabling nonclinical and chemistry, manufacturing and controls activities"
Chemistry, manufacturing and controls (CMC) is the package of technical information that explains how a drug or biologic is made, tested and kept consistent, submitted to regulators to demonstrate the product’s safety, purity and reliable production. Investors care because robust CMC lowers the risk of manufacturing delays, regulatory rejection or costly recalls — think of it as the product’s recipe and kitchen controls that determine whether a medicine can be scaled, sold and generate revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that its partner Spruce Biosciences (Nasdaq: SPRB) ("Spruce") has separated its CRHX-101 (formerly SPR-202 and HBM9013) program into Adrenyx Biosciences ("Adrenyx").

Logo

Adrenyx is a newly established, wholly-owned subsidiary of Spruce focused on endocrinology. This company is expected to be listed on Nasdaq in the first half of 2027. Upon completion of the planned pro rata distribution of Adrenyx common stock to Spruce shareholders, Harbour BioMed expects to hold equity interests in both Spruce and Adrenyx.

CRHX-101 is a monoclonal antibody designed to selectively neutralize corticotropin-releasing hormone (CRH), an upstream driver of adrenal androgen excess in classic congenital adrenal hyperplasia (CAH). By targeting CRH at the top of the hormonal signaling cascade, CRHX-101 is being developed with the potential to achieve durable upstream disease control and reduce patients' reliance on chronic high-dose glucocorticoid therapy, a longstanding challenge in CAH management. Adrenyx's near-term priorities include completion of IND-enabling nonclinical and chemistry, manufacturing and controls activities, the filing of an Investigational New Drug application for CRHX-101 with the U.S. Food and Drug Administration (the "FDA"), and initiation of a clinical program thereafter.

To support the development of CRHX-101, Adrenyx has secured an initial US$5 million under a secured convertible note purchase arrangement, with the potential to issue up to US$10 million in aggregate principal amount. In addition, a private placement of Adrenyx equity securities to institutional investors is expected to be completed in connection with the planned distribution, with up to US$50 million funded by the convertible notes investor, inclusive of the notes funding.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: "We are pleased to see the continued advancement of CRHX-101 through a dedicated corporate structure. The establishment of Adrenyx reflects a focused approach to advancing CRHX-101 and supporting its next stage of development. We look forward to the continued progress of CRHX-101 in addressing the significant unmet medical needs of people living with CAH."

CRHX-101 originated from HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by Harbour BioMed. In January 2025, HBMAT entered into a collaboration and license agreement with Spruce, granting Spruce exclusive rights to develop and commercialize this molecule outside Greater China (including mainland China, Hong Kong, Macau and Taiwan). Under the agreement, HBMAT is eligible to receive up to US$395 million, including upfront, development, regulatory and commercial milestone payments, as well as tiered royalties on future net product sales. Additionally, HBMAT was granted a warrant to receive minority interest in the partner. In January 2026, Harbour BioMed announced that its wholly-owned subsidiary had exercised the warrants.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harbour-biomeds-partner-spruce-biosciences-separates-crhx-101-program-into-adrenyx-biosciences-advancing-development-of-harbour-biomed-originated-antibody-through-a-standalone-company-302942976.html

SOURCE Harbour BioMed

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happened to Harbour BioMed-originated CRHX-101 at Spruce Biosciences?

Spruce separated CRHX-101 into Adrenyx Biosciences, a newly established, wholly-owned subsidiary focused on endocrinology. Adrenyx is expected to list on Nasdaq in the first half of 2027. Harbour BioMed expects to hold equity interests in both companies after the planned distribution of Adrenyx shares to Spruce shareholders.

What rights and payments does HBMAT's CRHX-101 agreement with Spruce cover?

The January 2025 agreement granted Spruce exclusive development and commercialization rights outside Greater China, including mainland China, Hong Kong, Macau and Taiwan in the excluded territory. HBMAT is eligible for up to US$395 million in upfront, development, regulatory and commercial milestone payments, plus tiered royalties on future net product sales.

How is Adrenyx financing CRHX-101 development?

Adrenyx secured an initial US$5 million under a secured convertible note purchase arrangement permitting up to US$10 million in aggregate principal. A private placement to institutional investors is expected alongside the planned distribution, with up to US$50 million funded by the notes investor, inclusive of notes funding.

Keep reading